Your browser doesn't support javascript.
loading
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients
Valentí Moreno, Vicente; Brunet Vidal, Joan; Manzano Alemany, Hermini; Salud Salvia, Antonia; Llobera Serentill, Montserrat; Cabezas Montero, Inés; Sonia Servitja Tormo, Sonia; Eugenia Sopena Bert, Eugenia; Gumà Padró, Josep.
Affiliation
  • Valentí Moreno, Vicente; Hospital de Sant Joan. Reus. Spain
  • Brunet Vidal, Joan; Hospital Dr Josep Trueta. Girona. Spain
  • Manzano Alemany, Hermini; Hospital Son Dureta. Palma de Mallorca. Spain
  • Salud Salvia, Antonia; Hospital Arnau de Vilanova. Lleida. Spain
  • Llobera Serentill, Montserrat; Hospital Verge de la Cinta. Tortosa. Spain
  • Cabezas Montero, Inés; Hospital de Sant Joan. Reus. Spain
  • Sonia Servitja Tormo, Sonia; Hospital de Sant Joan. Reus. Spain
  • Eugenia Sopena Bert, Eugenia; Hospital de Sant Joan. Reus. Spain
  • Gumà Padró, Josep; Universitat Rovira i Virgili. Reus. Spain
Clin. transl. oncol. (Print) ; 8(3): 208-212, mar. 2006. tab
Article in En | IBECS | ID: ibc-047656
Responsible library: ES1.1
Localization: ES1.1 - BNCS
RESUMEN
No disponible
ABSTRACT
Aim and background. Intestinal alkalization couldprevent irinotecan associated diarrhea modulatingsome chemical equilibria between irinotecan metabolites.The aim of this study was to evaluate the efficacyof this procedure in advanced gastrointestinalcancer patients (GICP).Materials and method. In this prospective studyadvanced GICP, receiving irinotecan based chemotherapyregimens, were well trained to add sodiumbicarbonate to the water intake in order to accomplishintestinal alkalization.Results. A total of twenty four advanced GICP wereenrolled. Grade III-IV diarrhea has been observedin four patients (16%), some of whom had severalrisk factors for diarrhea. Only one out of seventeencolorectal cancer patients, receiving the irinotecancombination as first line therapy, had grade III-IVdiarrhea. No side effects of the procedure have beenappreciated.Conclusions. Intestinal alkalization may be effectiveas a preventive treatment for irinotecan associateddiarrhea in chemotherapy regimens used in GICP.This procedure deserves further investigation
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Health and Well-Being / Neglected Diseases Health problem: Target 3.3: End transmission of communicable diseases / Target 3.4: Reduce premature mortality due to noncommunicable diseases / Diarrhea / Neglected Diseases Database: IBECS Main subject: Camptothecin / Diarrhea Type of study: Observational study / Risk factors Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2006 Document type: Article Institution/Affiliation country: Hospital Arnau de Vilanova/Spain / Hospital Dr Josep Trueta/Spain / Hospital Son Dureta. Palma de Mallorca/Spain / Hospital Verge de la Cinta. Tortosa/Spain / Hospital de Sant Joan. Reus/Spain / Universitat Rovira i Virgili/Spain
Search on Google
Collection: National databases / Spain Health context: SDG3 - Health and Well-Being / Neglected Diseases Health problem: Target 3.3: End transmission of communicable diseases / Target 3.4: Reduce premature mortality due to noncommunicable diseases / Diarrhea / Neglected Diseases Database: IBECS Main subject: Camptothecin / Diarrhea Type of study: Observational study / Risk factors Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2006 Document type: Article Institution/Affiliation country: Hospital Arnau de Vilanova/Spain / Hospital Dr Josep Trueta/Spain / Hospital Son Dureta. Palma de Mallorca/Spain / Hospital Verge de la Cinta. Tortosa/Spain / Hospital de Sant Joan. Reus/Spain / Universitat Rovira i Virgili/Spain
...